Psychoactive fungi

Cybin to Present at the Benzinga Global Small Cap Conference

Thursday, May 6, 2021 - 9:30pm

Learn about small cap investing with clearly defined educational modules, take a look at a curated group of small cap investment opportunities, and connect with the global small cap audience in an intimate, virtual setting.\nCybin makes no medical, treatment or health benefit claims about Cybin\xe2\x80\x99s proposed products.

Key Points: 
  • Learn about small cap investing with clearly defined educational modules, take a look at a curated group of small cap investment opportunities, and connect with the global small cap audience in an intimate, virtual setting.\nCybin makes no medical, treatment or health benefit claims about Cybin\xe2\x80\x99s proposed products.
  • The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products.
  • Cybin has not conducted clinical trials for the use of its proposed products.
  • Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.

Psyched Wellness Signs Supply Agreement for Amanita Muscaria

Tuesday, May 4, 2021 - 9:00am

The Company\'s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

Key Points: 
  • The Company\'s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.
  • Forward-looking information includes, but is not limited to, statements with respect to receiving the Initial Supply on the timelines and in quantities mentioned above, the quality and potency of the Amanita muscaria mushrooms received from MB MEMEL GOODS, the intended use of the Initial Supply and the Company\'s ability to reach commercial production.
  • Accordingly, readers should not place undue reliance on forward-looking information.
  • The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.\nTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/82702\n'

Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin

Wednesday, April 28, 2021 - 1:45pm

"A joint venture is the logical next step for us as it has the potential to provide cGMP grade psilocybin for use in clinical studies we plan to initiate in the future.

Key Points: 
  • "A joint venture is the logical next step for us as it has the potential to provide cGMP grade psilocybin for use in clinical studies we plan to initiate in the future.
  • "\nThe Agreement proposes that Core One Labs would develop and manage the cGMP production and delivery of biosynthetic psilocybin and Lobe would be responsible for the clinical development, and commercialization of the product(s).
  • Vocan Biotechnologies Inc. ("Vocan"), a wholly-owned subsidiary of Core One Labs, would produce the biosynthetic psilocybin and other psychedelic compounds to be used.
  • Vocan has identified a patentable method of producing psilocybin, the active ingredient in psychotropic mushrooms.\nThe structure and terms of the Joint Venture remains subject to negotiation between the parties.

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

Wednesday, April 28, 2021 - 1:45pm

Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.

Key Points: 
  • Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.
  • For most, psychedelic drugs conjure up images of the 1960\'s, hippies tripping out on LSD or magic mushrooms.
  • However, early studies are finding that psilocybin the active agent in magic mushrooms could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD).
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

Wednesday, April 28, 2021 - 1:45pm

Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.

Key Points: 
  • Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.
  • For most, psychedelic drugs conjure up images of the 1960\'s, hippies tripping out on LSD or magic mushrooms.
  • However, early studies are finding that psilocybin the active agent in magic mushrooms could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD).
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Monday, April 26, 2021 - 12:15pm

The severity of AUD\xe2\x80\x94mild, moderate, or severe\xe2\x80\x94is based on the number of criteria met.1\n"The evidence of increased alcohol use during this ongoing pandemic is startling.

Key Points: 
  • The severity of AUD\xe2\x80\x94mild, moderate, or severe\xe2\x80\x94is based on the number of criteria met.1\n"The evidence of increased alcohol use during this ongoing pandemic is startling.
  • For so many individuals and families, Alcohol Use Disorder can be disruptive, even devastating.
  • There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition.
  • Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.

Psirenity signs partnership with Jamaica’s Scientific Research Council to conduct joint studies into beneficial effects of psilocybin mushrooms

Thursday, April 1, 2021 - 1:00pm

TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has signed a two-year partnership with Jamaicas Scientific Research Council (SRC) to conduct cooperative studies into the beneficial effects of psilocybin mushrooms.

Key Points: 
  • TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has signed a two-year partnership with Jamaicas Scientific Research Council (SRC) to conduct cooperative studies into the beneficial effects of psilocybin mushrooms.
  • Under the new partnership, SRC, Jamaicas principal public sector agency responsible for scientific research and development, will provide technical support, technology transfer and physical and human resources that will allow Psirenity to develop imaginative new mental health treatments.
  • This new collaboration will help Psirenity streamline and scale-up production of psilocybin mushrooms to develop critical nutraceutical and pharmaceutical products, McCullough said.
  • Psirenity believes creating advanced psilocybin therapies for mental health and offering proprietary psycho-educational programs, as well as evidence-based therapeutics and nutraceuticals, can help advance human achievement through enhanced psychedelics.

Why Mainstream Mental-Health Care is Embracing Psilocybin - Alternative Active Substances

Wednesday, March 31, 2021 - 1:30pm

While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.

Key Points: 
  • While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.
  • A recent article on WIRED (UK) projected that Psychedelic medicine will begin to cross over into the mental health mainstream in 2021.
  • "In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat post-traumatic disorder (PTSD), and on psilocybin the active substance in magic mushrooms to treat depression.
  • In the UK, London-based mental-health care company COMPASS Pathways has raised more than $115m to fund its efforts and bring to market a psilocybin treatment for depression.

Why Mainstream Mental-Health Care is Embracing Psilocybin - Alternative Active Substances

Wednesday, March 31, 2021 - 1:30pm

While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.

Key Points: 
  • While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.
  • A recent article on WIRED (UK) projected that Psychedelic medicine will begin to cross over into the mental health mainstream in 2021.
  • "In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat post-traumatic disorder (PTSD), and on psilocybin the active substance in magic mushrooms to treat depression.
  • In the UK, London-based mental-health care company COMPASS Pathways has raised more than $115m to fund its efforts and bring to market a psilocybin treatment for depression.

Psyched Wellness Initiates Study on AME-1 Extract for Gut Health

Tuesday, March 30, 2021 - 12:00pm

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Key Points: 
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.
  • The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.
  • The Company is in the process of developing a line of Amanita Muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
  • This news release includes data that has been obtained from third party sources, including the findings from the Toxicology Assessment.